Annual financial statements of Merck Financial Services GmbH Annual Financial Statements 2023 Annual Financial Statements 2022 Annual Financial Statements 2021 Annual Financial Statements 2020 Annual Financial Statements 2019 Annual Financial Statements 2018 Annual Financial Statements 2017 Annual Financial Stat...
To Our Shareholders Management Report Corporate Governance Consolidated Financial Statements Notes Other Information de Suche Management Report Report on Economic Position Course of Business and Economic Position MeRck Group Download Merck Group Key figures Change € million 2023 2022 ...
Full-Year 2023 Financial Outlook Raises and Narrows Expected Worldwide Sales Range To Be Between $58.6 Billion and $59.6 Billion, Including Negative Impact of Foreign Exchange of Approximately 2 Percentage Points; Outlook Includes Approximately $1.0 Billion of LAGEVRIO Sales Now Expects Non-GAAP ...
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and exp...
Financial Summary $ in millions, except EPS amounts Fourth Quarter Year Ended 2023 2022 Change Change Ex-Exchange Dec. 31, 2023 Dec. 31, 2022 Change Change Ex-Exchange Sales $14,630 $13,830 6% 7% $60,115 $59,283 1% 4% GAAP net (loss) income1 (1,226) 3,017...
February 4, 2025 Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results January 31, 2025 Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults
2023 Financial Outlook Anticipates Full-Year 2023 Worldwide Sales To Be Between $57.2 Billion and $58.7 Billion; Outlook Includes Approximately $1.0 Billion of LAGEVRIO Sales Expects Full-Year 2023 GAAP EPS To Be Between $5.86 and $6.01; Expects Non-GAAP EPS To Be Between $6.80 and $6.9...
the 2023 10-K, identify certain risk factors and cautionary statements that could cause the company's actual results to differ materially from those projected in any of our forward-looking statements made this morning. Merck undertakes no obligation to publicly update any forward-looking statements....
future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year endedDecember 31, 2023, and the company’s other filings with theSecuritie...
Merck & Co Inc (NYSE:MRK) Q4 2022 Earnings Call dated Feb. 02, 2023. Corporate Participants: Peter Dannenbaum—Vice President, Investor Relations Robert M. Davis—Chairman and Chief Executive Officer Caroline Litchfield—Executive Vice President and Chief Financial Officer ...